Cullinan Oncology LLC (CGEM) - Total Liabilities
Based on the latest financial reports, Cullinan Oncology LLC (CGEM) has total liabilities worth $36.81 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Cullinan Oncology LLC's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Cullinan Oncology LLC - Total Liabilities Trend (2012–2025)
This chart illustrates how Cullinan Oncology LLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Cullinan Oncology LLC balance sheet assets.
Cullinan Oncology LLC Competitors by Total Liabilities
The table below lists competitors of Cullinan Oncology LLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Domino's Pizza Enterprises Limited
F:HQX
|
Germany | €2.01 Billion |
|
Swedish Logistic Property AB Series B
ST:SLP-B
|
Sweden | Skr11.22 Billion |
|
Hubei Jiuzhiyang Infrared System Co Ltd
SHE:300516
|
China | CN¥611.14 Million |
|
Bangkok Chain Hospital Public Company Limited
BK:BCH
|
Thailand | ฿3.28 Billion |
|
Shanghai Haixin Group Co Ltd A
SHG:600851
|
China | CN¥1.01 Billion |
|
Tianjin Printronics Circuit Corp
SHE:002134
|
China | CN¥1.57 Billion |
|
Jiangxi Firstar Panel Technology Co Ltd
SHE:300256
|
China | CN¥788.00 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Cullinan Oncology LLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Cullinan Oncology LLC (CGEM) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cullinan Oncology LLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cullinan Oncology LLC (2012–2025)
The table below shows the annual total liabilities of Cullinan Oncology LLC from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $39.64 Million | +25.87% |
| 2024-12-31 | $31.50 Million | +3.99% |
| 2023-12-31 | $30.29 Million | +16.10% |
| 2022-12-31 | $26.09 Million | +120.88% |
| 2021-12-31 | $11.81 Million | -17.94% |
| 2020-12-31 | $14.39 Million | -89.75% |
| 2019-12-31 | $140.37 Million | +153.88% |
| 2018-12-31 | $55.29 Million | +9461.03% |
| 2016-12-31 | $578.28K | -53.55% |
| 2015-12-31 | $1.24 Million | +8.10% |
| 2014-12-31 | $1.15 Million | +12.08% |
| 2013-12-31 | $1.03 Million | +218.11% |
| 2012-12-31 | $323.00K | -- |
About Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049,… Read more